摘要
目的:研究低分子肝素(LMWHs)治疗脑梗死的疗效。方法:52例脑梗死患者随机分成肝素组及对照组各26例。2组均给予神经内科常规治疗,肝素组同时于治疗第1天开始腹壁皮下注射LMWHs 0.4 ml,每日2次,连续7 d。治疗前及治疗后3、71、4 d行神经功能缺损(NDS)评分,并治疗后第14 d评定临床疗效。结果:肝素组治疗后各时间点NDS评分均明显低于对照组(P<0.01),并且显效率和总有效率均高于对照组(P<0.01)。结论:LMWHs可阻止脑梗死症状进一步加重,在短时间内改善伤残程度,临床疗效明显且无明显副作用。
Objective To evaluate efficacy and safety of low-molecular-weight heparin in treatment acute ischemic strokes. Methods 52 patents who did not fit the time-window criteria for thrombolytic therapy were randomly assigned to low-molecular-weight heparin therapy or danshen therapy （control group）. The patents were evaluated by rating neuralgic defects and disabilities. Results Efficacy rate in the low-molecular-weight heparin group was 84.6%, significantly higher than 50.0% in the controls （P〈0.01）. No obvious side effects was found during lowmolecular-weight heparin therapy. Conclusion Low-molecular-weight heparin therapy is a safe and effective therapy to treat acute ischemic strokes.
出处
《神经损伤与功能重建》
2006年第3期163-164,共2页
Neural Injury and Functional Reconstruction
关键词
低分子肝素
脑梗死
low-molecular-weight heparin
ischemic stroke
